Delcath Systems (OTCMKTS: DCTHD) and Wright Medical Group (NASDAQ:WMGI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.
Valuation and Earnings
This table compares Delcath Systems and Wright Medical Group’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Delcath Systems||$1.99 million||0.12||-$17.97 million||($1,377.67)||0.00|
|Wright Medical Group||$690.36 million||3.51||-$432.37 million||($2.65)||-8.65|
Delcath Systems has higher earnings, but lower revenue than Wright Medical Group. Wright Medical Group is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
This table compares Delcath Systems and Wright Medical Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Wright Medical Group||-38.40%||-6.27%||-1.71%|
Volatility and Risk
Delcath Systems has a beta of -0.59, indicating that its share price is 159% less volatile than the S&P 500. Comparatively, Wright Medical Group has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Delcath Systems and Wright Medical Group, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Wright Medical Group||0||4||8||0||2.67|
Wright Medical Group has a consensus price target of $32.22, suggesting a potential upside of 40.65%. Given Wright Medical Group’s higher possible upside, analysts clearly believe Wright Medical Group is more favorable than Delcath Systems.
Wright Medical Group beats Delcath Systems on 9 of the 11 factors compared between the two stocks.
Delcath Systems Company Profile
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Wright Medical Group Company Profile
Wright Medical Group, Inc. is a global specialty orthopaedic company. The Company through Wright Medical Technology, Inc. (WMT) and other subsidiaries provides extremity and biologic solutions that enable clinicians to alleviate pain and restore the patients’ lifestyles. The Company operates through three segments: U.S., International and BioMimetic. The Company’s business includes products that are used in foot and ankle repair, upper extremity products and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and patients. The Company’s products include extremity hardware, foot and ankle hardware, upper extremity hardware and biologics.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.